Skip To Main Content
This website is intended exclusively for healthcare professionals residing and/or working in the UAE.
Campus
Campus

No Rebound Effect Post Clopidogrel Withdrawal

Watch the video of subgroup analysis of the Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events (CHANCE) trial showed no rebound increase in the risk of ischemic stroke, stroke, transient ischemic attack (TIA), and composite events during the 90 days after discontinuation of clopidogrel therapy in patients with TIA or minor stroke.

Related articles
DAPT in Elderly with CAD Meta Analysis
  • Atherothrombosis
  • Atherothrombosis

DAPT in Elderly with CAD Meta Analysis

Watch the video and get to know more on the crucial insights from this systematic review and meta-analysis of DAPT in elderly patients with acute coronary syndrome (ACS). Dual oral antiplatelet therapy (DAPT) with prasugrel or ticagrelor is associated with a higher risk of bleeding events in elderly patients with ACS compared to clopidogrel, with no difference in primary efficacy endpoint rates between the treatment groups.

Read article
Effectiveness and safety of Clopidogrel vs Aspirin
  • Atherothrombosis
  • Atherothrombosis

Effectiveness and safety of Clopidogrel vs Aspirin

Read article
MAT-BH-2300434/V1/JUN2023